Genmab

Genmab appears in 130. 谁才是生物医药行业发展的核心驱动力？兼谈创新药产业链的角色分工 as a company that can have very valuable products while still depending on larger partners for commercialization. The source uses Genmab to show why product success alone does not automatically equal full global pharma commercialization.

Connections

• BioTech To BioPharm Transition - boundary between product development and full commercialization.
• Global Pharma Commercialization - capability Genmab helps clarify by contrast.
• Biotech License-Out Arbitrage - adjacent value-capture concern when commercial rights sit with larger partners.